New hope for rare cancers: drug duo shows promise
NCT ID NCT03074513
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 22 times
Summary
This study tests a combination of two drugs, atezolizumab and bevacizumab, in people with rare solid tumors that are hard to treat. The goal is to see if the drugs can shrink or control the cancer by boosting the immune system and blocking blood supply to tumors. About 133 adults with cancers like Merkel cell, nasopharyngeal, or mesothelioma are taking part. The treatment is not a cure, but aims to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.